Skip to content
Dementia Atlas
Home
Explore
Bottlenecks
Where diagnosis, trials, and care get stuck.
Ideas
Hypotheses that name a proposed test.
Knowledge graph
Walk diagnosis to treatment to trial to idea.
Clinical trials
Recruiting NCT links and landmark studies.
Approvals & access
Labelled regional notes — licence is not funding.
Watchlist
Investigational products; not home protocols.
Diagnoses
Alzheimer's and other dementia types on the map.
Who
Companies, institutions, and cited public figures.
Impact portfolio
DALYs-per-dollar framing with Not estimated gaps.
Care guide
Household next steps — secondary to the science map.
First stages
Early signs and what to look for.
Glossary
Terms used on the map and in clinics.
Impact
Treatments
Who
Care guide
Resources
companies
companies
Who is building what.
Type:
Any
Country:
Any
3
companies
Save view
Download
CSV
JSON
Name
↕
Type
↕
Stage
↕
HQ
Country
↕
Products
↓
Technologies
↕
Biogen
Cambridge, MA, US
Biogen partnered on lecanemab and previously marketed aducanumab.
Large pharma
-
none
Cambridge, MA
US
2
0
Eli Lilly
Indianapolis, US
Lilly developed donanemab and is running further amyloid-antibody studies.
Large pharma
-
none
Indianapolis
US
2
0
Eisai
Tokyo, JP
Eisai is a medicines company that co-developed lecanemab.
Large pharma
-
none
Tokyo
JP
1
0
